Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024)
Capricor Therapeutics (CAPR) recorded quarterly EBIT Margin of 236.91% in Q4 2024, up 141.18% quarter-over-quarter from 575.24% in Q3 2024, and up 24751.0% on a YoY basis from N/an in Q1 2024.
Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBIT Margin history runs 14 years deep, the most recent figure standing at 236.91% for Q4 2024.
- In Q4 2024, EBIT Margin rose 24751.0% year-over-year to 236.91%; the TTM figure through Sep 2025 stood at 472.73% (down 34509.0% YoY), while the FY2024 annual figure was 38.16%, up 5747.0% from the prior year.
- EBIT Margin was 236.91% for Q4 2024 at Capricor Therapeutics, up from 575.24% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 236.91% in Q4 2024 to a low of 23211.04% in Q3 2020.
- Historically, EBIT Margin has averaged 3517.42% across 5 years, with a median of 491.12% in 2022.
- The sharpest annual moves came in 2020 and 2021: EBIT Margin sank 2206537 bps in 2020, then surged 450397 bps in 2021.
- A 5-year view of EBIT Margin shows it stood at 7229.02% in 2020, then surged by 66 bps to 2490.75% in 2021, then soared by 66 bps to 840.33% in 2022, then soared by 99 bps to 10.6% in 2023, then surged by 2335 bps to 236.91% in 2024.
- The last three EBIT Margin figures came in at 236.91% (Q4 2024), 575.24% (Q3 2024), and 291.86% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 236.91% |
| Sep 30, 2024 | -575.24% |
| Jun 30, 2024 | -291.86% |
| Mar 31, 2024 | -102.66% |
| Dec 31, 2023 | -10.60% |
| Sep 30, 2023 | -110.97% |
| Jun 30, 2023 | -197.76% |
| Mar 31, 2023 | -274.04% |
| Dec 31, 2022 | -840.33% |
| Sep 30, 2022 | -407.00% |
| Jun 30, 2021 | -2,490.75% |
| Mar 31, 2021 | -12,644.77% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -23,211.04% |
| Jun 30, 2020 | -6,994.72% |
| Mar 31, 2020 | -1,134.94% |
| Dec 31, 2019 | -667.88% |
| Sep 30, 2019 | -1,145.67% |
| Jun 30, 2019 | -503.39% |
| Mar 31, 2019 | -1,109.38% |